Total Payments
$184,004
2024 Payments
$19,081
Companies
36
Transactions
128
Medicare Patients
677
Medicare Billing
$180,981
Payment Breakdown by Category
Consulting$95,206 (51.7%)
Other$45,718 (24.8%)
Research$28,423 (15.4%)
Travel$12,869 (7.0%)
Food & Beverage$1,789 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $95,206 | 36 | 51.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,718 | 11 | 23.8% |
| Unspecified | $28,423 | 18 | 15.4% |
| Travel and Lodging | $12,869 | 13 | 7.0% |
| Honoraria | $2,000 | 1 | 1.1% |
| Food and Beverage | $1,789 | 49 | 1.0% |
Payments by Type
General
$155,581
110 transactions
Research
$28,423
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $32,114 | 9 | $0 (2022) |
| Eli Lilly and Company | $21,691 | 12 | $0 (2024) |
| F. Hoffmann-La Roche AG | $20,988 | 11 | $0 (2023) |
| PFIZER INC. | $19,658 | 20 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $19,124 | 4 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $19,080 | 4 | $0 (2022) |
| Helsinn Healthcare SA | $10,631 | 6 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $9,641 | 13 | $0 (2024) |
| Daiichi Sankyo Inc. | $5,525 | 3 | $0 (2024) |
| EISAI INC. | $5,165 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,081 | 35 | PFIZER INC. ($6,364) |
| 2023 | $28,120 | 23 | F. Hoffmann-La Roche AG ($15,626) |
| 2022 | $45,234 | 15 | JAZZ PHARMACEUTICALS INC. ($19,080) |
| 2021 | $22,443 | 14 | Eli Lilly and Company ($5,600) |
| 2020 | $20,006 | 6 | Eli Lilly and Company ($13,300) |
| 2019 | $19,301 | 18 | Helsinn Healthcare SA ($10,631) |
| 2018 | $3,359 | 5 | Incyte Corporation ($1,711) |
| 2017 | $26,459 | 12 | Bayer HealthCare Pharmaceuticals Inc. ($17,778) |
All Payment Transactions
128 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $18.12 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.69 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $29.56 | General |
| 10/03/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: DESMOID TUMORS | ||||||
| 10/01/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 09/13/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $62.07 | General |
| 09/11/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.10 | General |
| 08/27/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug), Odomzo | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: Oncology | ||||||
| 08/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: Oncology | ||||||
| 07/08/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: Oncology | ||||||
| 06/18/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.46 | General |
| Category: Oncology | ||||||
| 06/11/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Oncology | ||||||
| 06/10/2024 | Lilly USA, LLC | RETEVMO (Drug) | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| Category: Oncology | ||||||
| 05/31/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $77.09 | General |
| 05/30/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $53.20 | General |
| 04/26/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $32.61 | General |
| Category: Oncology | ||||||
| 04/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.78 | General |
| Category: Oncology | ||||||
| 04/11/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 04/11/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Oncology | ||||||
| 03/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BAY94 9343 Solid Tumor Multi Cohort Trial | Bayer HealthCare Pharmaceuticals Inc. | $17,778 | 3 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,540 | 4 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,600 | 3 |
| BLU667 1101 ARROW ongoing | F. Hoffmann-La Roche AG | $1,551 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,450 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,184 | 1 |
| GEDATOLISIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 94 | 201 | $99,666 | $19,998 |
| 2022 | 5 | 231 | 568 | $256,597 | $59,691 |
| 2021 | 3 | 164 | 580 | $257,451 | $62,585 |
| 2020 | 6 | 188 | 456 | $180,177 | $38,708 |
Total Patients
677
Total Services
1,805
Medicare Billing
$180,981
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 83 | 183 | $96,624 | $19,126 | 19.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 11 | 18 | $3,042 | $871.93 | 28.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 144 | 424 | $217,824 | $48,018 | 22.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 52 | $14,716 | $4,334 | 29.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 37 | 56 | $9,219 | $3,062 | 33.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 18 | $10,298 | $2,824 | 27.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 12 | 18 | $4,540 | $1,454 | 32.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 110 | 483 | $238,851 | $56,444 | 23.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 30 | 58 | $9,090 | $3,249 | 35.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 24 | 39 | $9,510 | $2,892 | 30.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 87 | 266 | $127,269 | $23,213 | 18.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 35 | 100 | $23,480 | $6,438 | 27.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 20 | 41 | $11,829 | $3,537 | 29.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 19 | $9,761 | $3,165 | 32.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 17 | 17 | $4,746 | $1,500 | 31.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 13 | $3,092 | $855.53 | 27.7% |
About Dr. Vivek Subbiah, MD
Dr. Vivek Subbiah, MD is a Pediatric Hematology-Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1174726384.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vivek Subbiah, MD has received a total of $184,004 in payments from pharmaceutical and medical device companies, with $19,081 received in 2024. These payments were reported across 128 transactions from 36 companies. The most common payment nature is "Consulting Fee" ($95,206).
As a Medicare-enrolled provider, Subbiah has provided services to 677 Medicare beneficiaries, totaling 1,805 services with total Medicare billing of $180,981. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Other Specialties Pediatrics, Hematology & Oncology
- Location Houston, TX
- Active Since 06/06/2007
- Last Updated 01/03/2011
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1174726384
Products in Payments
- Non-Covered $17,778
- ZEPZELCA (Drug) $15,360
- Enhertu (Drug) $5,525
- MEKINIST (Drug) $4,875
- Alecensa (Biological) $3,465
- RETEVMO (Drug) $3,250
- Lenvima (Drug) $3,125
- KISQALI (Drug) $2,757
- IMFINZI (Biological) $2,740
- LORBRENA (Drug) $2,025
- ELREXFIO (Drug) $1,880
- Gavreto (Drug) $1,551
- TAGRISSO (Drug) $1,422
- Ixempra (Drug) $1,306
- TAFINLAR (Drug) $1,184
- Oncology Testing (Device) $1,012
- Zelboraf (Biological) $796.16
- Abraxane (Drug) $114.10
- Non-Covered Product (Drug) $100.00
- FOUNDATIONONE (Device) $67.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Houston
Helen Heslop, Md, MD
Pediatric Hematology-Oncology — Payments: $73,908
Pediatric Hematology-Oncology $73,908
Dr. Jenny Despotovic, D.o, D.O
Pediatric Hematology-Oncology — Payments: $71,551
Pediatric Hematology-Oncology $71,551
Jennifer Foster, Md, MD
Pediatric Hematology-Oncology — Payments: $41,045
Pediatric Hematology-Oncology $41,045
Dr. Venee Tubman, M.d, M.D
Pediatric Hematology-Oncology — Payments: $32,728
Pediatric Hematology-Oncology $32,728
Youngna Lee-Kim, Md, MD
Pediatric Hematology-Oncology — Payments: $29,576
Pediatric Hematology-Oncology $29,576
Carl Allen, Md, MD
Pediatric Hematology-Oncology — Payments: $28,385
Pediatric Hematology-Oncology $28,385